Gautschi, Oliver, Milia, Julie, Cabarrou, Bastien, Bluthgen, Marie-Virginia, Besse, Benjamin ORCID: 0000-0001-5090-8189, Smit, Egbert F., Wolf, Juergen, Peters, Solange, Frueh, Martin, Koeberle, Dieter, Oulkhouir, Youssouf, Schuler, Martin, Curioni-Fontecedro, Alessandra, Huret, Benjamin, Kerjouan, Mallorie, Michels, Sebastian, Pall, Georg, Rothschild, Sacha ORCID: 0000-0003-1304-9340, Schmid-Bindert, Gerald, Scheffler, Matthias ORCID: 0000-0002-9031-1368, Veillon, Remi, Wannesson, Luciano, Diebold, Joachim, Zalcman, Gerard, Filleron, Thomas and Mazieres, Julien (2015). Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. J. Thorac. Oncol., 10 (10). S. 1451 - 1458. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Full text not available from this repository.

Abstract

Introduction: Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib, dabrafenib, and sorafenib as BRAF inhibitors are currently tested in clinical trials, but access for patients is limited. The aim of this study was to document the clinical course of patients treated outside of clinical trials. Methods: We conducted a retrospective multicenter cohort study in Europe of patients with advanced BRAF-mutant lung cancer treated with known BRAF inhibitors. Data were anonymized and centrally assessed for age, gender, smoking, histology, stage, local molecular diagnostic results, systemic therapies, and survival. Best response was assessed locally by RECIST1.1. Results: We documented 35 patients treated in 17 centers with vemurafenib, dabrafenib, or sorafenib. Median age was 63 years (range 42-85); gender was balanced; 14 (40%) were never smokers; all (100%) had adenocarcinoma; 29 (83%) had V600E; 6 (17%) had other mutations; one of them had a concomitant KRAS mutation. Thirty (86%) patients had chemotherapy in the first line. Overall survival with first-line therapy was 25.3 months for V600E and 11.8 months for non-V600E. Thirty-one patients received one BRAF inhibitor, and four received a second inhibitor. Overall response rate with BRAF therapy was 53%, and disease control rate was 85%. Median progression-free survival with BRAF therapy was 5.0 months, and overall survival was 10.8 months. Conclusions: These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma. Further trials are warranted to study combination therapies and drug resistance mechanisms.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Gautschi, OliverUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Milia, JulieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cabarrou, BastienUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bluthgen, Marie-VirginiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Besse, BenjaminUNSPECIFIEDorcid.org/0000-0001-5090-8189UNSPECIFIED
Smit, Egbert F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Peters, SolangeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Frueh, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Koeberle, DieterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Oulkhouir, YoussoufUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schuler, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Curioni-Fontecedro, AlessandraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huret, BenjaminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kerjouan, MallorieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Michels, SebastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pall, GeorgUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rothschild, SachaUNSPECIFIEDorcid.org/0000-0003-1304-9340UNSPECIFIED
Schmid-Bindert, GeraldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheffler, MatthiasUNSPECIFIEDorcid.org/0000-0002-9031-1368UNSPECIFIED
Veillon, RemiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wannesson, LucianoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Diebold, JoachimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zalcman, GerardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Filleron, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mazieres, JulienUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-391729
DOI: 10.1097/JTO.0000000000000625
Journal or Publication Title: J. Thorac. Oncol.
Volume: 10
Number: 10
Page Range: S. 1451 - 1458
Date: 2015
Publisher: ELSEVIER SCIENCE INC
Place of Publication: NEW YORK
ISSN: 1556-1380
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CLINICOPATHOLOGICAL FEATURES; CLINICAL CHARACTERISTICS; MUTATED MELANOMA; B-RAF; MUTATIONS; VEMURAFENIB; ADENOCARCINOMA; DABRAFENIB; PATHWAY; TRIALMultiple languages
Oncology; Respiratory SystemMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/39172

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item